Lutein Spray Formula

Lutein and Zeaxanthin were identified in 1995 as the only two Carotenoid antioxidants specific to lens and macula health. Selectively accumulated from plasma and deposited in the lens, macula, and lungs; Lutein and Zeaxanthin filter light and serve as potent free radical scavengers. The macular pigment composed of Lutein and Zeaxanthin, functions as a colour filter to protect the light-sensitive photoreceptor cells (responsible for visual acuity) from visible blue and ultraviolet light-originated free radical damage. Studies in 1997:

1. Showed a 30% reduced macular pigment density in eyes with AMD.

2. Found a correlation between reduced macular pigment density and increased lens density (cataracts) in seniors; and

3. Demonstrated that macular pigment density can be increased with dietary and/or supplemental Lutein. Maintaining sufficient levels of Lutein & Zeaxanthin (the only Carotenoid antioxidants active in the retina) can prevent ARMD and Cataracts and preserve youthful visual sensitivity.

“Most individuals supplementing with sublingual Lutein and Zeaxanthin report reduced glare and visual fatigue; improved contrast sensitivity”

Vinpocetine (vin-po-seh-teen) an extract from periwinkle seeds (vinca major) has been well researched and available in Europe for the past twenty years. Recently, it became available as a dietary supplement. Vinpocetine has been included in this formula for safer and more effective circulatory benefits to the entire retina. There are no known negative interactions with other dietary supplements or drugs.

Vinpocetine facilitates cerebral metabolism, which affects the retina and the front part of the brain. It increases blood flow, steps up the concentration of ATP (the energy carrying molecules of the cells) and thus improves utilisation of glucose and oxygen in the brain and retina. Vinpocetine also increases the turnover of Norepenephrine and Serotonin. It inhibits abnormal platelet aggregation, improves red blood cell elasticity, and inhibits an enzyme (GMP) that causes arterial constriction and blood flow reduction. Thus, arteries relax, blood pressure normalises and blood flow increases. In clinical studies, Vinpocetine has been shown to benefit depression, headaches, short-term memory, inner-ear conditions, tinnitus, vertigo, menopause, insomnia, speech impairment, stroke and eyesight disorders.

In one study, 100 predominantly atherosclerotic patients with eye disorders were given Vinpocetine. Eighty-eight subjects displayed increased retinal circulation and improved visual acuity. Half of the group that showed the best response, had conditions caused by central retinal artery insufficiency. Prior to giving Vinpocetine, dye was visible through fluorescein angiographies in the choroid only and not in the retinal arteries.

After giving Vinpocetine, dye entered the retinal arteries. The greatest improvement in circulation was seen in the macula. Functional improvements were seen in the macular region in particular.

Results were most favourable with glaucoma, macular degeneration, and diabetic retinopathy.

Absorption of Sublingual Nutrient

Absorbed* (Approx) in a healthy system 

Product 2mg daily Lutein Cost Maintenance Amount needed 10mg daily Lutein Cost Therapeutic Amount needed Total dose in Pack Cost per Pack Lutein available per dose*
New Focus 16p 1 Spray 83p 6 Sprays 160sprays 24.95 2mg
I-Caps 66p 4 Tabs £3.33p 20 Tabs 60 Tablets 10.00 0.5mg
Ocuvite Lutein £1.10 4 Tabs £4.72 17 Tabs 36 Tablets 10.00 0.6mg
Quest Eye Nutrients 62p 4 Tabs £3.13 17 Tabs 30 Tablets 9.39 0.6mg
Vision Ace 1.16p 5 Caps £5.75 25 Tabs 30 Caps 7.00 0.4mg
Solgar Lutein Lycopene Carotene £1.00 2 Caps £5.00 10 Caps 30 Caps 15.00 1.00mg
VisualEyes 30p 2 Caps £3.00 9 Caps 30 Caps 9.00 1.00
Centrum Silver £13.00 80 Tabs £132.00 400 Tabs 30 Tabs 10.00 0.025mg
Sanatogen Gold £7.99 72 Tabs £40.00 363 Tabs 90 Tabs 10.00 0.0275mg

*Absorption Rates only in a HEALTHY Digestive tract. Absorption of Lutein available per dose from tablets and Caps may decrease if unhealthy tract. Intra-Oral is not effected by digestive tract health.

Dosage:

Preventative: 1 Spray twice daily.
Maintenance: 1 Spray 3 times daily.
Therapeutic: 1 Spray 5 times daily.

Best taken a minimum of 10 minutes after liquids and 1 hour after food. Drop Lutein Spray under the tongue and hold for 2 minutes. Allow 10 minutes before food or drink.

Recommended dosage: 5 sprays per day for the first two months then 3 sprays per day for the next two months and lastly 1 spray per day as a preventative.

Sublingual Supplement Facts

Serving Size: 6 Spray 1ml
Serving Per Container: Approx 30

Amount Per Serving compared to Tablets or Capsules

Ingredient Amount per serving Equal to tablets of %Daily Value
Lutein 10.00mg 100.00mg *
L-Glycine 5.00mg 50.00mg *
L-Taurine 5.00mg 50.00mg *
Zeaxanthin 100mcg 1000mcg *
Bilberry extract 5.0mg 50.00mg *
Gingko Biloba (24% Extract) 1.0mg 10.00mg *
*Daily Value not established
Other Ingredients: Purified Water, Glycerin, Natural Flavours, Lecithin, Vitamin E.

PRECAUTIONS & CONTRAINDICATIONS

Persons with a tendency toward hypotension (low blood pressure) should begin taking Lutein Spray Formula at a reduced dosage and monitor their blood pressure.

Not recommended for use during pregnancy.
Another reason for more Lutein… It Prevents Cancer

Unless you’ve been living in a cave for the past five years, you probably know that eating fruits and vegetables reduces your risk for getting certain types of cancer. Scientists have been slowly unraveling the complex reasons why – primarily, it is because fruits and vegetables contain antioxidant compounds that prevent cell damage. Lutein, a Carotenoid (plant pigment) in the same chemical class as beta-carotene, is one of these compounds. Carotenoids provide the colourful palette of reds, yellows, and greens you see in vegetables and flowers, and even adorn birds, fish, and butterflies.

So what do Carotenoids have to do with your colon?

In a recent study at the University of Utah Medical School, researchers found that of all the many Carotenoids that occur in vegetables, Lutein has the strongest protective effects against colon cancer, and contributes to a better prognosis in certain cases of colon cancer.

The researchers looked at the eating habits of 1,993 patients with colon cancer and 2,410 cancer-free participants, and then used a table of food Carotenoids content to determine how much of the various types of Carotenoids each person consumed.

They weighed this information against cancer occurrence, stage, and prognosis for all study participants. The Utah team found that when a daily diet contains ample sources of Lutein – spinach, broccoli, tomatoes, oranges, celery, eggs, and lettuce and other greens are good sources – men and women are 17 percent less likely to develop colon cancer. In addition, they determined that cancer patients whose colon cancer developed before they had reached the age of 67, or whose tumours occurred further up the colon, reaped the most significant benefits from Lutein.

People in the study were between the ages of 30 and 79. The researchers were unable to draw any significant correlation between the other types of dietary Carotenoids and reduced risks of colon cancer or improved prognosis. However, these other Carotenoids have already shown their ‘colours’ in other ways.

Lycopene, known to protect eyes against age-related disease, also protects prostate cells from cancer (as does Lutein) and is found in: Red, Yellow, Orange and Green Vegetables (especially cooked or tinned tomatoes) – Eat the Rainbow!

References:

Slattery M, Benson J, Curtin K, et al. Carotenoids and colon cancer Am J Clin Nutr 2000; 71 (2): 575-582.

Cohen JH, et al. Fruit and vegetable intakes and prostate cancer risk. J Nat Cancer Inst. 2000 Jan 5;92 (1):61-8.

Giovannucci E, et al. Intake of Carotenoids and retinol in relation to risk of Prostate cancer. J Natl Cancer Inst. 1995 Dec 6;87(23):1767-76.

Enger SM, et al. Dietary intake of specific Carotenoids and vitamins A, C, and E, and prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1996 Mar; 5(3): 147-53.